Can you get Suboxone for kratom online?
As of July 2026: Yes.
Buprenorphine/naloxone (Suboxone) for opioid use disorder can currently be prescribed via telehealth without a prior in-person medical evaluation. This includes treatment for kratom and concentrated 7-OH dependence, which is managed as an opioid-type use disorder. A DEA-registered prescriber licensed in your state can evaluate you by video and send a prescription to your local pharmacy, often the same day.
The rules governing this have been extending for several years and are actively being formalized. Current telehealth flexibilities run through December 31, 2026, alongside a permanent buprenorphine-specific telemedicine rule that took effect December 31, 2025. Check the date on this page before relying on it for specific compliance questions, and see the regulatory section below for current status.
At a glance: getting Suboxone for kratom online (as of July 2026)
Key Takeaways
- Buprenorphine for kratom dependence can be prescribed via telehealth right now, without a prior in-person visit, under rules currently in effect through the end of 2026.
- A permanent buprenorphine-specific telemedicine rule also took effect December 31, 2025, creating a lasting pathway alongside the temporary extension.
- Kratom and 7-OH dependence qualifies. These are managed as opioid-type use disorder, which is the approved indication for buprenorphine, making the telehealth pathway applicable.
- The process is fully home-based. Video evaluation, prescription to your local pharmacy, guided induction, and follow-up visits can all happen without leaving home.
- Legitimate telehealth providers operate under DEA rules with real clinical evaluations. Reputable programs are not pill mills; they follow the same clinical and regulatory standards as any licensed prescriber.
The current telehealth buprenorphine rules
The ability to prescribe buprenorphine via telehealth without an initial in-person visit originated during the COVID-19 public health emergency in 2020. What began as a temporary flexibility has been extended multiple times and is now supported by both temporary and permanent rule structures.
Fourth Temporary Extension (in effect through December 31, 2026): On December 30, 2025, the DEA and HHS published a Fourth Temporary Extension of COVID-19 telemedicine flexibilities, allowing DEA-registered practitioners to prescribe Schedule III-V controlled substances (which includes buprenorphine) via telehealth without a prior in-person evaluation through December 31, 2026. This extension gives the DEA and HHS additional time to finalize permanent regulations.
Expansion of Buprenorphine Treatment via Telemedicine Encounter (effective December 31, 2025): This final rule, published January 17, 2025 and effective December 31, 2025, creates a permanent pathway specifically for buprenorphine prescribing via telehealth. Under this rule, DEA-registered practitioners can prescribe buprenorphine for OUD via audio-video or, under certain conditions, audio-only encounters.
How they interact: As of July 2026, both the temporary extension and the permanent buprenorphine rule are active simultaneously. Practitioners may use the temporary extension (which has fewer requirements) through 2026, even if they also qualify under the permanent rule. Most reputable telehealth providers use the temporary extension pathway during 2026 while the regulatory landscape continues to settle.
What is still required:
- The prescriber must be DEA-registered with Schedule III-V prescribing authority
- The prescriber must be licensed in the state where you are located
- A genuine clinical evaluation must take place (this is not a rubber stamp; the prescriber reviews your history and determines clinical appropriateness)
- State telehealth laws may add requirements; most states permit this pathway
What is not required under the current rules:
- An in-person medical visit before the first prescription
- An in-person drug screen before initiation (though some providers request one)
- A specific number of prior treatment attempts
Does telehealth Suboxone work for kratom specifically?
Yes. Kratom and concentrated 7-OH dependence involves mu-opioid receptor adaptation, which is the same pharmacological mechanism as classical opioid use disorder. Buprenorphine, the FDA-approved medication for OUD, works by stabilizing the same receptor system that kratom and 7-OH act on.
This is an off-label use of buprenorphine, meaning no kratom-specific FDA indication exists. But it is clinically supported by published case reports, a 2022 case series (Broyan et al., Substance Abuse), and a 2026 AIM Clinical Cases paper that describes buprenorphine as the preferred treatment for kratom and 7-OH dependence. Licensed prescribers apply OUD treatment principles because the pharmacology is the same.
Whether buprenorphine is right for your specific situation is a clinical judgment your provider makes during the evaluation. Some cases, for example people with milder leaf-based kratom use and no prior failed attempts, may be appropriate for other approaches. The evaluation is where that determination is made.
How the online process works
Step 1: The evaluation
You schedule a telehealth visit with a licensed provider. The visit typically involves:
- Review of your kratom or 7-OH use history: products, frequency, how long, recent changes
- Medical and mental health history
- Current medications
- When you last used
- Your goals and questions
The provider uses this information to determine whether buprenorphine treatment is appropriate and whether telehealth induction is suitable for your situation. A legitimate evaluation is a real clinical conversation, not a five-minute checkbox.
Step 2: The prescription
If the provider determines treatment is appropriate, a buprenorphine prescription is sent electronically to your preferred pharmacy. This often happens the same day or the following morning. Buprenorphine/naloxone is available as a generic and covered by most insurance.
Step 3: Guided induction
Your provider gives you instructions on when to take the first dose, specifically, to wait until you are in mild-to-moderate withdrawal to avoid precipitated withdrawal. For most kratom and 7-OH users, this means waiting approximately 12 to 24 hours after your last dose. Your provider guides the timing and what to expect.
For the full induction picture, see How to Switch From Kratom to Suboxone and Suboxone Precipitated Withdrawal After Kratom.
Step 4: Follow-up and stabilization
After induction, you have follow-up telehealth visits, typically weekly or biweekly early in treatment and monthly once stabilized. Your provider adjusts the dose based on how you are doing, monitors for side effects, and guides the longer-term plan, whether that is ongoing maintenance or an eventual supervised taper.
What it costs and what insurance covers
Many insurance plans cover buprenorphine treatment for opioid use disorder. Federal mental health and substance use parity laws require most insurance plans to cover OUD treatment at rates comparable to other medical care. Medicaid in most states covers buprenorphine treatment. Medicare Part D covers the medication.
Generic buprenorphine/naloxone is available at major pharmacies and is significantly less expensive than brand-name Suboxone. Cash-pay options exist for uninsured patients, and some patient assistance programs reduce or eliminate medication costs.
Bicycle Health accepts most major insurance and can verify your coverage before your first visit. See current pricing and insurance options.
How to choose a legitimate telehealth provider
Not every online prescriber operates the same way. A legitimate telehealth provider:
- Conducts a real clinical evaluation, not a five-minute approval form
- Requires prescribers to be DEA-registered and licensed in your state
- Follows DEA-compliant telemedicine protocols
- Provides ongoing monitoring and follow-up, not just a one-time prescription
- Offers or refers to additional supports if needed
Bicycle Health providers are licensed addiction-medicine clinicians operating under DEA regulations. Appointments are available seven days a week in most states, with same-day availability in many locations.
Frequently Asked Questions
Can you get buprenorphine online without an in-person visit?
Yes, under the current federal rules. The DEA and HHS Fourth Temporary Extension allows DEA-registered practitioners to prescribe buprenorphine via telehealth without a prior in-person visit through December 31, 2026. A permanent buprenorphine-specific telemedicine rule also took effect December 31, 2025. Both rules are currently in effect.
Is telehealth Suboxone for kratom as effective as in-person treatment?
Research on telehealth buprenorphine treatment for OUD generally shows the same or better treatment retention compared to in-person treatment. A 2023 JAMA Network Open study of Medicaid enrollees found that people who started buprenorphine via telehealth were more likely to remain in treatment at 90 days than those who started in-person settings. While that study was not kratom-specific, the medication and pharmacological mechanisms are the same.
Will insurance cover Suboxone for kratom treatment?
Most private insurance, Medicare, and Medicaid cover buprenorphine for opioid use disorder. Whether the specific indication on the prescription (OUD) is covered does not depend on which substance drove the dependence. Prior authorization may be required, and formulary tier and copay vary by plan. Bicycle Health's care team can verify your coverage before your first visit.
How long does it take to start treatment?
Many patients are evaluated and receive a prescription the same day they reach out. After the prescription is sent to your pharmacy, the timing of your first dose depends on the induction wait window, typically 12 to 24 hours after your last kratom or 7-OH dose. The acute discomfort of kratom withdrawal is addressed quickly once the first dose is taken at the right time.
What if I am not sure whether I need treatment?
The evaluation is a low-commitment step. It is a clinical conversation, not a commitment to a particular treatment course. Many people who schedule an evaluation are uncertain about whether they need help or which approach fits. The provider's job is to assess your situation and help you make an informed decision, not to push any specific outcome.
Sources
- Drug Enforcement Administration and U.S. Department of Health and Human Services. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register. Published December 30, 2025; effective December 31, 2025 through December 31, 2026. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
- Drug Enforcement Administration and U.S. Department of Health and Human Services. Expansion of Buprenorphine Treatment via Telemedicine Encounter. Federal Register. 90 FR 6504. Published January 17, 2025; effective December 31, 2025. https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter
- Barrett E, Hendy L, Lira MC, et al. What Clinicians Should Know About Kratom and 7-OH Mitragynine. AIM Clinical Cases (Annals of Internal Medicine: Clinical Cases). 2026;5:e251249. doi:10.7326/aimcc.2025.1249. https://www.acpjournals.org/doi/10.7326/aimcc.2025.1249
- Broyan VR, Brar JK, Allgaier Student T, et al. Long-term buprenorphine treatment for kratom use disorder: a case series. Substance Abuse. 2022;43:763-766. doi:10.1080/08897077.2021.2010250. PMID: 35112990.
- Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for Medicaid enrollees. JAMA Network Open. 2023;6(10):e2336914. doi:10.1001/jamanetworkopen.2023.36914.
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Publication No. PEP21-02-01-002. SAMHSA; 2021. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder-executive-summary/pep21-02-01-003
- American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. ASAM; 2020.
- U.S. Food and Drug Administration. FDA and Kratom. FDA; updated February 2026. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- National Institute on Drug Abuse. Medications for Opioid Use Disorder. NIDA. Updated May 2025. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
- Alliance for Connected Care. DEA Prescribing of Controlled Substances: Regulatory Timeline. Updated June 2026. https://connectwithcare.org/dea-prescribing-of-controlled-substances/